Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

ADRx Inc
Profile last edited on: 10/12/23      CAGE: 6XZ21      UEI: JQ76MYFLKYB4

Business Identifier: Advancing drug candidates for Alzhiemer’s disease, systemic amyloidosis, and ovarian cance
Year Founded
2013
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2260 Townsgate Road Suite 2
Westlake Village, CA 91361
   (310) 795-5388
   N/A
   www.adrxpharma.com
Location: Single
Congr. District: 26
County: Ventura

Public Profile

ADRx Inc is usefully understood as a preclinical biotechnology company leveraging proprietary structure-based technology to develop small molecule disaggregators and inhibitors targeting previously undruggable misfolded proteins in neurodegenerative diseases. The firm's pipeline consists of tau, TDP-43 and alpha-synuclein programs. Principals of the firm are scaling up the assays for high-content imaging analyses and describe what they're doing as developing cell-based assays to probe disease mechanisms associated with aberrant protein aggregation and biomolecular condensation

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,002,910
Phase II Dollars
$0
Total Awarded
$1,002,910

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $270,276
Project Title: Development of a Blood-based Diagnostic for Early Detection of Transthyretin Amyloidosis
2022 1 NIH $256,083
Project Title: Therapeutic Immunodepletion of a Transthyretin Aggregation Intermediate
2022 1 NIH $476,551
Project Title: Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease

Key People / Management

  Marcin Apostol -- President

  Albert Lim -- Scientist

Company News

There are no news available.